ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "infliximab"

  • Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting

    Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

    Yoshiya Tanaka1, Koji Oba2,3, Takao Koike4,5, Nobuyuki Miyasaka6, Tsuneyo Mimori7, Tsutomu Takeuchi8, Shintaro Hirata9, Eiichi Tanaka10, Hidekata Yasuoka11, Yuko Kaneko8, Kosaku Murakami7, Tomohiro Koga12, Kazuhisa Nakano13, Koichi Amano14, Kazuyasu Ushio15, Tatsuya Atsumi16, Masayuki Inoo17, Kazuhiro Hatta18, Shinichi Mizuki19, Shohei Nagaoka20, Shinichiro Tsunoda21, Hiroaki Dobashi22, Nao Horie3 and Norihiro Sato3, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, 3Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, 4Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, 5NTT Sapporo Medical Center, Sapporo, Japan, 6Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 9Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 10Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, 12Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, 13The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 14Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 15Ushio Clinic, Osaka, Japan, 16Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 17Utazu hospital, Utatsu-cho, Japan, 18Department of General Medicine, Tenri Hospital, Tenri, Japan, 19Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, 20Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 21Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 22Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan

    Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
  • Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting

    Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab

    Ana Martínez1,2, Chamaida Plasencia2,3, Victoria Navarro-Compán2, Borja Hernández-Breijo2, Dora Pascual-Salcedo2, Pilar Nozal4, Cristina Diego4, Irene Monjo2,3, Laura Nuño3,5 and Alejandro Balsa2,6, 1Immunology. La Paz University Hospital, Madrid, Spain, 2Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain, 4La Paz University Hospital, Immunology, Madrid, Spain, 5Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
  • Abstract Number: 2320 • 2017 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years

    Annelle Reed1, Surabhi S. Vinod2, Jamelle Maxwell3, Esraa M. A. Eloseily4,5, Matthew L. Stoll4 and Randy Q. Cron4, 1Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Childrens of Alabama, Birmingham, AL, 4Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Pediatrics, Assiut University, Assiut, Egypt

    Background/Purpose: The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of…
  • Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial

    Guro Løvik Goll1, Kristin Kaasen Jørgensen2, Joe Sexton1, Inge C Olsen3, Nils Bolstad4, Merete Lorentzen5, Espen A. Haavardsholm6, Cato Mork7, Jorgen Jahnsen8 and Tore K Kvien9, 1Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 7Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, 8Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 9Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 2904 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)

    Deborah Puyraimond-Zemmour1, Catherine Chapelon-Abric2, David Saadoun3, Diane Bouvry4, Marc Ruivard5, Marc Andre6, Laurent Perard7, Pascal Sève8 and Patrice Cacoub9, 1Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France, Paris, France, 2AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, 3Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, 4Hopital Avicenne, Department of Pneumology, Bobigny, France, Bobigny, France, 5CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, 6CHU Montpied, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, 7Department of Internal Medicine, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France, 8Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 9Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    Background/Purpose: CS is a life-threatening condition that accounts for 85% of sarcoidosis-related deaths in Japan and 13-25% in America. The objective is to evaluate the…
  • Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting

    Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab

    Lorie A. Ellis1, Ismail Simsek2, Lin Xie3, Adesuwa Ogbomo3, Dennis Parenti4, Kavitha Goyal4 and Yusuf Yazici5, 1Janssen HECOR Immunology, Horsham, PA, 2Guven Hospital, Ankara, Turkey, 3STATinMED Research Inc., Ann Arbor, MI, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5New York University School of Medicine, New York, NY

    Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
  • Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting

    Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis

    Joseph Tkacz1, Edward Lee2, Robert Low2, Jeffrey Stark2, Mohamed Yassine2 and Brenna Brady1, 1Health Analytics LLC, Columbia, MD, 2UCB Pharma, Smyrna, GA

    Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
  • Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting

    Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US

    Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX

    Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
  • Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting

    Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University

    Katelyn Banschbach1, Ellen Go2 and Stacey Tarvin3, 1Indiana University School of Medicine, Indianapolis, IN, 2Pediatrics, Indiana University School of Medicine, Indianapolis, IN, 3Riley Hospital for Children, Indiana University, Indianapolis, IN

    Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
  • Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting

    Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?

    Ryan Funk1, Valentina Shakhnovich2, Leon van Haandel3 and Mara L Becker4, 1University of Kansas Medical Center, Kansas City, KS, 2Gastroenterology and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, 3Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, 4Rheumatology, Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…
  • Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting

    Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy

    Eileen Pagano1, Myriam Kline2 and B. Anne Eberhard3, 1Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 2Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, 3Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY

    Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
  • Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium

    Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients

    Daniel Groth1, Sivia Lapidus2, Simona Nativ2 and Maria Perez3, 1Goryeb Children's Hospital, Morristown, NJ, 2Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, 3Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ

    Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
  • Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting

    Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway

    Guro Løvik Goll1,2, Inge C Olsen3, Kristin K Jorgensen4, Merete Lorentzen5, Nils Bolstad6, Espen A. Haavardsholm7, Knut EA Lundin8, Cato Mork9, Jorgen Jahnsen4, Tore K Kvien3 and the NOR-SWITCH study group, 1Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway, 8Dept of gastroenterology, Rikshospitalet, Oslo, Norway, 9Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

      Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of  spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA),  Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting

    Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice

    L Tweehuysen1, B.J.F. van den Bemt2, I.L. van Ingen3, A.J.L. de Jong4, W.H. van der Laan5, F.H.J. van den Hoogen5 and A.A. den Broeder5, 1Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 2Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 3Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, 4Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, 5Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose:  Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
  • Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting

    Strategies for Biological Drug Quantification in Biological Drug Immune Responses

    Michael Kruse Meyer1,2, Marlene Andersen1,3, Troels Vindbæk Stausbo4, Tue Bjerg Bennike4,5, Grethe Neumann Andersen1,6 and Allan Stensballe3,4, 1Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, 2Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, 3Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, 4Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, 5Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, 6Center for Clinical Science, Aalborg University, Hjørring, Denmark

    Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology